Tazemetostat hydrobromide - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for tazemetostat hydrobromide and what is the scope of patent protection?
Tazemetostat hydrobromide
is the generic ingredient in one branded drug marketed by Epizyme Inc and is included in one NDA. There are twenty-four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Tazemetostat hydrobromide has three hundred and thirty-six patent family members in thirty-eight countries.
One supplier is listed for this compound.
Summary for tazemetostat hydrobromide
International Patents: | 336 |
US Patents: | 24 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 12 |
Clinical Trials: | 2 |
DailyMed Link: | tazemetostat hydrobromide at DailyMed |
Recent Clinical Trials for tazemetostat hydrobromide
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 1 |
National Cancer Institute (NCI) | Phase 1/Phase 2 |
US Patents and Regulatory Information for tazemetostat hydrobromide
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for tazemetostat hydrobromide
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Croatia | P20190074 | See Plans and Pricing | |
Spain | 2750199 | See Plans and Pricing | |
Canada | 2887243 | METHODES DE TRAITEMENT DU CANCER (METHODS OF TREATING CANCER) | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |